불안장애 및 우울증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품별, 적응증별, 지역별, 경쟁별(2020-2030년)

The Global Anxiety Disorders and Depression Treatment Market, valued at USD 11.27 Billion in 2024, is projected to experience a CAGR of 5.93% to reach USD 15.92 Billion by 2030. The Global Anxiety Disorders and Depression Treatment Market encompasses a range of pharmacological interventions, including antidepressants, anxiolytics, and mood stabilizers, alongside various psychotherapeutic modalities and neurostimulation techniques designed to alleviate symptoms and improve outcomes for individuals suffering from these pervasive mental health conditions.

Key Market Drivers

The Global Anxiety Disorders and Depression Treatment Market is significantly influenced by the escalating worldwide incidence of mental health conditions and ongoing innovations in therapeutic strategies. The rising global prevalence of anxiety and depression disorders directly expands the addressable patient population requiring interventions, thereby acting as a fundamental growth catalyst for the market. This demographic shift necessitates broader access to diagnostic tools and diverse treatment options.

Key Market Challenges

The substantial economic burden linked to developing and delivering novel therapeutic solutions directly impedes the growth of the Global Anxiety Disorders and Depression Treatment Market. The extensive research and development phases for new antidepressants, anxiolytics, and advanced neurostimulation techniques necessitate considerable financial investment. These high costs ultimately translate into elevated pricing for new treatments, making them less accessible, particularly in regions with limited healthcare budgets and less developed infrastructure.

Key Market Trends

The expansion of digital therapeutics and telehealth solutions significantly influences the anxiety disorders and depression treatment market by enhancing accessibility and scalability of care. These platforms leverage technology to deliver evidence-based interventions remotely, reaching a broader patient population, particularly in underserved areas. According to GSMA's Mobile Economy 2024 report, approximately 5.6 billion people worldwide were mobile service subscribers in 2023, providing a vast infrastructure for these digital health services.

Key Market Players

• Abbvie Inc.
• Bristol-Myers Squibb Company
• Eli Lily & Co
• GlaxoSmithKline Plc
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc
• Pfizer Inc
• Sanofi
• Axsome Therapeutics Inc

Report Scope:

In this report, the Global Anxiety Disorders and Depression Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anxiety Disorders and Depression Treatment Market, By Product:

• Antidepressant Drugs
• Therapy and Devices
• Others

Anxiety Disorders and Depression Treatment Market, By Indication:

• Obsessive-Compulsive Disorder
• Major Depressive Disorder
• Phobia
• Others

Anxiety Disorders and Depression Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anxiety Disorders and Depression Treatment Market.

Available Customizations:

Global Anxiety Disorders and Depression Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anxiety Disorders and Depression Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Antidepressant Drugs, Therapy and Devices, Others)
  • 5.2.2. By Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Anxiety Disorders and Depression Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anxiety Disorders and Depression Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
  • 6.3.2. Canada Anxiety Disorders and Depression Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
  • 6.3.3. Mexico Anxiety Disorders and Depression Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication

7. Europe Anxiety Disorders and Depression Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anxiety Disorders and Depression Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
  • 7.3.2. France Anxiety Disorders and Depression Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
  • 7.3.3. United Kingdom Anxiety Disorders and Depression Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
  • 7.3.4. Italy Anxiety Disorders and Depression Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
  • 7.3.5. Spain Anxiety Disorders and Depression Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication

8. Asia Pacific Anxiety Disorders and Depression Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anxiety Disorders and Depression Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
  • 8.3.2. India Anxiety Disorders and Depression Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
  • 8.3.3. Japan Anxiety Disorders and Depression Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
  • 8.3.4. South Korea Anxiety Disorders and Depression Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
  • 8.3.5. Australia Anxiety Disorders and Depression Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication

9. Middle East & Africa Anxiety Disorders and Depression Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anxiety Disorders and Depression Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
  • 9.3.2. UAE Anxiety Disorders and Depression Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
  • 9.3.3. South Africa Anxiety Disorders and Depression Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication

10. South America Anxiety Disorders and Depression Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anxiety Disorders and Depression Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
  • 10.3.2. Colombia Anxiety Disorders and Depression Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
  • 10.3.3. Argentina Anxiety Disorders and Depression Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anxiety Disorders and Depression Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol-Myers Squibb Company
• 15.3. Eli Lily & Co
• 15.4. GlaxoSmithKline Plc
• 15.5. H. Lundbeck A/S
• 15.6. Johnson & Johnson Services, Inc.
• 15.7. Merck & Co. Inc
• 15.8. Pfizer Inc
• 15.9. Sanofi
• 15.10. Axsome Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer